Promoted by Dr Krishna Ella, the vaccine manufacturer serves both domestic and export markets and remains entirely promoter-owned. As of July 31, 2025, the promoter family held 100% equity stake in the company, directly or indirectly India for Deeper Cooperation in R&D, Biotech, Pharma with Switzerland · Pandorum Technologies Secures $18Mn Series B to Advance Programmable Tissue Regenerative Therapies · Bharat Coking Coal Lists at 96% Premium, Shares Cool After Strong Debut · BCCL IPO Boosts Confidence as Coal India Weighs More Subsidiary listings: CM Bharat Biotech, the developer of Covaxin, is considering an IPO that could raise over $500 million, a report claimed. However, as these businesses are largely tender-driven, they expose the company to revenue volatility from potential tender losses and limit pricing flexibility, as per ICRA. This risk is partly offset by Bharat Biotech’s established manufacturing capabilities and long-standing supply relationships with these agencies. While OPV historically accounted for a large portion of Bharat Biotechs revenue, the company’s reliance on it has declined as volumes of TCV, RV and JE vaccines have steadily increased.

Original title: “Covaxin Maker Bharat Biotech Considers IPO, Likely to Raise $500 Mn – Outlook Business”

Vaccine developer Bharat Biotech International Ltd is mulling over a public listing that is expected to raise over $500 million. Bharat Biotech IPO: Vaccine developer Bharat Biotech International Ltd is mulling over a public listing that is expected to raise over $500 million. Established in 1996, Bharat Biotech has delivered more than 9 billion vaccines worldwide. Its range of products includes vaccines for covid-19, and hepatitis B, including remedies for diarrhea and burns. The company's consideration over an initial public offering (IPO) comes after the Union Budget 2026 earmarked Rs 10,000 crore for the South Asian nation's bio-pharma industry. India’s market for first-time share sales has had a slow start to 2026 after two consecutive years of record fundraising. Stocks have been pressured by slowing earnings growth, global trade uncertainty and uneven foreign inflows. Large offerings in the pipeline include those of wireless carrier Jio Platforms Ltd., National Stock Exchange of India Ltd. Krishna Ella, said, biotechnology has been explicitly recognised with a ₹10,000 crore allocation over five years to catalyse the nation’s BioPharma Shakti, effectively almost doubling the Department of Biotechnology’s budget.

Original title: “Vaccine Developer Bharat Biotech Said To Consider $500 Million IPO | Republic World”

Aside from creating a toxic work environment, CBER Director Vinay Prasad has also been accused of berating his staff and retaliating against reviewers who questioned his decisions.

Original title: “Prasad Under Probe for Promoting Workplace Toxicity, Staffers Say”

Indian vaccine developer Bharat Biotech International Ltd. is considering an initial public offering that may raise more than $500 million, according to people familiar with the matter. Founded in 1996, Bharat Biotech says it has delivered more than 9 billion vaccines worldwide. Its products include vaccines for Covid-19 and hepatitis B, as well as remedies for burns and diarrhea. ... Unlock 500+ Stock Recos on AppIndia’s market for first-time share sales has had a slow start to 2026 after two consecutive years of record fundraising. NFO Alert: TRUST Mutual Fund announces launch of TRUSTMF Mid Cap Fund Edtech working with Ivy League universities first to file for Gujarat's GIFT City IPO

Original title: “Vaccine maker Bharat Biotech said to mull $500 million IPO - The Economic Times”

Generate Biomedicines sold 25 million shares at $16 each to raise $400 million, funding late-stage trials of an AI‑engineered asthma antibody and sharpening debates over access and trial equity. Generate’s IPO is one of the largest recent biotech offerings, following several sizable new listings this year, and it highlights how capital markets continue to shape which biomedical innovations move fastest from platform to patient. The offering will fund late-stage clinical work on the company’s lead program, GB-0895, an anti-TSLP antibody engineered with artificial intelligence to extend dosing intervals. Generate plans two Phase 3 trials in severe asthma that are expected to enroll about 1,600 patients combined, with full enrollment projected by the first half of 2028, and an ongoing Phase 1b study testing the antibody in chronic obstructive pulmonary disease. For patients and public health systems, the IPO accelerates a transition from research to trials that could change management of severe asthma. An antibody engineered to last as long as six months between doses, if proven safe and effective, could reduce hospital visits and daily medication burdens for people with severe disease. As the company moves into registrational studies, policymakers and public health advocates will watch closely for signals about trial inclusivity, downstream pricing, and how publicly traded biotech financing affects equitable access to breakthrough therapies. www.biopharmadive.comwww.iposcoop.comwww.reuters.comwww.fiercebiotech.comwww.renaissancecapital.comwww.biospace.com

Original title: “Generate Biomedicines prices $400 million IPO to advance AI-designed asthma drug | Prism News”

The Company has listed on Nasdaq under the ticker symbol GENB Backing from venture capital fund Flagship Pioneering, as well as partnerships with Novartis and Amgen, gives the IPO a high degree of credibility with institutional investors, the expert adds. "Recent examples show that biotech companies partnering with big pharma are often future takeover targets, promising investors significant premiums," Muehlbauer noted. The company utilizes artificial intelligence that designs innovative protein drugs to treat a variety of diseases. The company is headquartered in Somerville, Massachusetts. The main stake in the company (57.7%) before the IPO belonged to the head of Flagship Nubar Afeyan (one of the founders of Moderna), according to Reuters and Bloomberg. Generate Bio positions itself as a next-generation biotech company combining machine learning, bioengineering and medicine. Generate Bio is seeking to go public at a time when the number of IPOs in biotechnology and pharmaceuticals is rising sharply, Bloomberg reports. According to the agency, since the beginning of the year, initial public offerings of companies such as Aktis Oncology and Veradermics have already brought in $1.4 billion. Based on the results of the IPO, the value of the entire company can be estimated at about $2 billion, Bloomberg notes. The listing was organized by Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities and Cantor. In 2023, Generate Bio raised $273 million in a Series C funding round that included investors such as Amgen (Nvidia's venture capital arm), MAPS Capital (invested in BioNTech) and Pictet Alternative Advisors.

Original title: “IPO Generate Biomedicines: shares of AI drug development platform become available – Oninvest”

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate:Biomedicines is the latest biotech to benefit from a renewed interest among investors for publicly listed drug developers. There’s also GB-5267, an armored, MUC16-directed CAR-T developed in partnership with the Roswell Park Comprehensive Cancer Center and initially being aimed at platinum-resistant ovarian cancer. The biotech has previously said that $15 million of the proceeds will be needed to take GB-4362 and GB-5267 into the clinic. 'When the markets opened, we were ready': Why biotech IPOs are back for 2026 Beyond the $300 million needed for its phase 3 studies, Generate has plenty of other ways to spend the IPO proceeds. They include $100 million to complete an ongoing phase 1b study of GB-0895 for chronic obstructive pulmonary disease and then to initiate the next phase of clinical development. Generate has also estimated that $75 million will be required to fund platform innovation and carry several programs through development candidate nomination and into investigational-new-drug-enabling activities. Nally agreed that it had been a “pretty dark winter for biotech over the last few years in terms of the IPO market.” · He attributed a “really nice rise” in the XBI biotech index in the later months of 2025, combined with a “wave of mergers and acquisitions,” as fueling a renewed interest from investors in the sector.

Original title: “Generate lands largest biotech IPO since 2024 with $400M listing”

Through creation of registries and repositories to increase access to small patient populations and few samples, innovative clinical trial designs that reduce participation burden, and unique therapeutic development approaches for personalized medicine, CDMRP-funded rare disease research overcomes ... In fiscal year 2026, the CDMRP received congressional appropriations to address rare cancers and several rare diseases and conditions with potential to impact Service Members during or after service, or their Family members, impacting military readiness. Through creation of registries and repositories to increase access to small patient populations and few samples, innovative clinical trial designs that reduce participation burden, and unique therapeutic development approaches for personalized medicine, CDMRP-funded rare disease research overcomes clinical challenges and accelerates treatment development. Developing treatments for rare diseases means working with small and globally dispersed patient populations and limited data, requiring highly creative and collaborative teams to identify and test new interventions. The CDMRP supports research in unique treatment approaches and innovative clinical trial designs for rare diseases, overcoming these challenges and accelerating treatment development for patients with few options. “This has been invaluable to bring the therapy closer to clinic.” · Oro’s work also demonstrates potential for translation to other types of wounds, including combat wounds experienced on the battlefield. “While the therapy focuses on helping the rare disease patients, it has broader impacts to heal poorly closing wounds for civilians, Service Members and Veterans due to injury or degeneration,” Oro said. “We believe this [study] has created a framework that can now be scaled to many other rare cancers, resources that empower labs everywhere, and the starting points for therapeutic trials that civilians, Service Members and Veterans can participate in,” Boehm said. Home-Based Strategies Increase Patient Participation in Epidermolysis Bullosa Clinical Trials

Original title: “DVIDS - News - CDMRP Funds Research to Accelerate Treatments for Rare Diseases to Support Warfighters and their Families”

The BioSpace team hit the ground running at the J.P. Morgan Healthcare Conference earlier this month to bring you the news from the streets of San Francisco.

Original title: “Deep Dive: BioSpace Takes On JPM26 in San Francisco”

One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as February comes to a close.Generate Biomedicines (GENB) priced its IPO at the midpoint to raise $400 million at a $2.2 billion market cap. One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as February comes to a close.Generate Biomedicines (GENB) priced its IPO at the midpoint to raise $400 million at a $2.2 billion market cap. - Renaissance Capital The Flagship Pioneering-incubated biotech is using its AI platform, which combines programmable capabilities with biohardware and data, to develop drugs with both precision and scale. Its most advanced candidate is in Phase 3 trials for severe asthma. Generate finished down 21%. The week’s six blank check IPOs were led by MOZAYYX Acquisition (MZYX.U), which raised $261 million to target fintech, energy, cybersecurity, and other high-growth areas. Three IPOs submitted initial filings this week, led by Healthpeak Properties’ senior housing REIT Janus Living (JAN), which we estimate could raise up to $500 million. They were joined by a direct listing, Canada-based The Metals Royalty Co. (TMCR). Two SPACs also submitted initial filings. RMG ML Sports Holdings (SHOTU) plans to raise $261 million, and Dune Acquisition III (DUNU.RC) plans to raise $150 million. As of 2/26/2026, the Renaissance IPO Index was down 0.6% year-to-date, while the S&P 500 was up 1.1%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include CoreWeave (CRWV) and Kenvue (KVUE). The Renaissance International IPO Index was up 16.4% year-to-date, while the ACWX was up 11.2%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Kioxia and Galderma.

Original title: “IPO News - US IPO Weekly Recap: Asthma-focused Generate Biomedicines closes out February IPO market”

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.

Original title: “Generate caps a strong month for biotech IPOs with $400M offering”

Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering comes as the IPO market remains volatile, with swings in high-growth technology stocks driven by concerns that artificial intelligence could disrupt established businesses and industries. Recent sell-offs have delayed IPO plans of several firms, with analysts noting that successful listings generally depend on strong investor sentiment.

Original title: “Drug developer Generate Biomedicines raises $400 million in US IPO | Reuters”

IPO prices at $16 for 25M shares, raising $400M for the clinical-stage generative biology firm. GENB begins Nasdaq trading Feb. 27, deal closing Mar. 2. MARA Announces Strategic Partnership with Starwood to Accelerate ... (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of Generate will raise gross proceeds of $400 million from the IPO at $16.00 per share. Underwriters have a 30-day option to purchase up to 3,750,000 additional shares at the IPO price.

Original title: “AI-driven drug designer Generate Biomedicines launches $400M IPO”

The Clinical Center of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to Bionic Power Inc., a company organized in British Columbia, Canada.

Original title: “Prospective Grant of an Exclusive Patent License: Powered Gait Assistance Systems and Gait Assistance Systems and Methods of Control Thereof”

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years. STAT A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA View all ... Developing an Array of Diverse Vaccine Platforms Webinar - on demand • Provided by BioPharma Dive's studioID; Sponsored content by Novavax in partnership with studioID GB-0895 is in early-stage testing in chronic obstructive pulmonary disease, too. Results are anticipated this year. Generate’s pipeline also includes two cancer therapies that could soon enter the clinic. Previously, the company had been testing a COVID-19 drug codenamed GB-0669, but it shelved the treatment in 2025 amid waning interest for coronavirus therapies. Generate also laid off dozens of employees that year. Including Generate’s offering, five biotechs have now banked nearly $1.4 billion in total IPO proceeds in February, making it the most active month for new stock offerings in more than a year, according to BioPharma Dive data. CNBC FDA Commissioner Dr. Makary on rare disease therapy approvals, internal politics at the agency According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

Original title: “Generate caps a strong month for biotech IPOs with $400M offering | BioPharma Dive”

Every Cure, a biotech nonprofit started by University of Pennsylvania researcher David Fajgenbaum, will use the funds to advance its AI tool that matches existing drugs with rare diseases. His experience inspired him to find ways to identify treatments for others with rare diseases. Read moreSteven M. Falk / Staff Photographer ... Published Feb. 26, 2026, 12:22 p.m. ET · Every Cure, a biotech nonprofit started by a University of Pennsylvania researcher, has landed $76 million in federal funding to advance its artificial intelligence match-making tool that identifies existing drugs to treat rare diseases. Over the next three years, Philadelphia-based Every Cure will use the funding from the Advanced Research Projects Agency for Health (ARPA-H) to pursue preclinical studies for at least 20 drugs that show promise for being repurposed for rare diseases with no other treatment options. Every Cure’s AI tool expedites a drug discovery process that is otherwise often left to chance. When patients with rare diseases have few treatment options, doctors may scour medical journals or tap expert networks for leads on other drugs to try with mixed results. The nonprofit was co-founded in 2022 by David Fajgenbaum, an associate professor at University of Pennsylvania, after his own experience with a rare disease.

Original title: “Philly-based Every Cure gets $76M in funding from ARPA-H for rare disease AI tool”

The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.

Original title: “Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer”

After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.

Original title: “After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral”

While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.

Original title: “Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+”

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral semaglutide in blood sugar control and weight reduction—albeit with a few extra discontinuations as compared to its rival.

Original title: “Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front”